CO-CSG
11.6.2019 14:02:05 CEST | Business Wire | Press release
As new digital services are deployed to help communications service providers (CSPs) drive innovation, 5G core networks are becoming a necessity to enable true service differentiation. This need is quickly becoming realized, with two-thirds of organizations1 planning to deploy 5G by the end of next year. Not only will CSPs be expected to deliver a fully functional 5G network to meet end-user demand, but success will lie in the ability to provide innovative digital services and to fully monetize their 5G infrastructure investment.
Today, CSG announced the availability of its new 5G Dynamic Charging Function, designed to help CSPs optimize their strategy to not only deliver the value of 5G networks to customers, but also to optimize for sustainable growth in the digital economy. This new capability fulfils the roles of both the 5G Charging Function (CHF) and the Charging Gateway Function (CGF), providing offline and online mediation functionality in a single platform, while managing the complexity of all interfaces between the network and the BSS functions.
“The revenue potential resulting from the deployment of 5G networks should not be underestimated,” said Chad Dunavant, global head of product management, CSG. “But the next generation of business, from 5G to the Internet of Things, requires fundamentally new businesses models. The CSG 5G Dynamic Charging Function gives CSPs the foundation they need to capitalize and monetize on complete industry transformation.”
The CSG 5G Dynamic Charging solution enables operators to:
- Drive service differentiation : Facilitate the monetization of network slicing, enabling charging of tenants and differentiated services by charging in-slice and across slices.
- Minimize risk and disruption to existing systems : Provides a cost effective and efficient way for service providers to seize the 5G opportunity.
- Elastically scale : Automatically scale up to process large charging volumes and down when traffic subsides to optimize infrastructure costs.
- Deliver unparalleled capacity : Process millions of transactions a second with low cost infrastructure to deploy.
- Automate operations : With intelligent tools for diagnostics and troubleshooting.
- Support critical services : Single-digit latencies for real-time online charging transactions.
- Be vendor independent : Support network functions and OSS/BSS systems from any vendor. Eliminates network equipment provider siloes.
- Preserve existing investments : Seamlessly manage the integration of service-based interfaces to existing online charging system interfaces for faster time to market.
With hundreds of global installations, CSG has one of the most trusted mediation and transaction management solutions in the world. CSG supports mediation across any domain, across all mediation functions, for all deployment approaches. The solution captures and processes customer usage events of all kinds from any service delivery network for industry leaders in digital communications and media, financial services, logistics and government.
For more information on how to effectively monetize 5G, download the latest CSG whitepaper here .
About CSG
CSG (NASDAQ: CSGS) is a provider of software and services that help companies around the world monetize and digitally enable the customer experience. For more than 35 years, CSG has simplified the complexity of business, providing revenue management and digital monetization, payments, and customer engagement solutions to help our customers tackle any business challenge and thrive in an ever-changing marketplace.
Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually. CSG is the trusted partner driving digital innovation for hundreds of leading global brands, including Arrow Electronics, AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, iflix, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn , Twitter and Facebook .
1 Gartner 5G Adoption Survey, December 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005208/en/
Contact:
Brad Jones Public Relations CSG +1 (303) 200-3001 brad.jones@csgi.com Liz Bauer Investor Relations CSG +1 (303) 804-4065 liz.bauer@csgi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom